
Journal of Medicinal Chemistry p. 516 - 521 (1983)
Update date:2022-08-05
Topics:
Neumeyer, John L.
Reischig, Dirk
Arana, George W.
Campbell, Alexander
Baldessarini, Ross J.
et al.
The enantiomers <(S)-(+) and (R)-(-)> of N-n-propylnorapomorphine (NPA) were synthesized. (R)-NPA was obtained by the acid-catalyzed rearrangement of N-n-propylnormorphine. (R)-NPA also was converted to (RS)-N-n-propylnorapomorphine dimethyl ether by dehydrogenation of the 10,11-O,O'-dimethyl ether of (R)-NPA with 10percent palladium on carbon in acetonitrile, followed by reduction with sodium cyanoborohydride under acidic conditions.Alternatively (RS)-NPA 10,11-O,O'-dimethyl ether was obtained via total synthesis. (+)-Dibenzoyl-D-tartaric acid was used to resolve (RS)-NPA dimethyl ether.Ether cleavage gave (S)-NPA isolated as the hydrochloride salt in greater than 99.9percent enantiomeric purity, as determined by circular dichroism (CD) spectra.The pharmacological activities of (S)- and (R)-NPA were evaluated with subnanomolar concentrations of 3H-labeled apomorphine (APO), ADTN, and spiroperidol (SPR) for competition for binding to a membrane-rich subsynaptosomal fraction of calf caudate nucleus.IC50 (nM) values for (R)-NPA vs. (S)-NPA were as follows: <3>APO, 2.5 vs. 66; <3>ADTN, 2.0 vs. 60; <3>SPR, 174 vs. 1400.The efficacy of (R)- and (S)-NPA in stimulating dopamine-sensitive adenylate cyclase from both homogenates of rat corpus striatum and pieces of intact carp retina was also evaluated.Three behavioral effects in the rat (stereotyped behavior, sedation, and catalepsy) were also examined.Only (R)-NPA induced stereotypy; (S)-NPA failed to antagonize this action of the R isomer.The effects of (R)- and (S)-NPA on adenylate cyclase agreed with the behavioral effects and radioreceptor binding assays in that the R isomer was the strongly preferred enantiomer at dopamine receptors.The S enantiomer of NPA was, however, the weakly preferred configuration for rat liver catechol O-methyltransferase.A dopamine-receptor model accommodates the configuration of NPA and related aporphines
View MoreShanghai Xinda Pharmaceuticals Co., Ltd.
Contact:86-21-33692333-8008
Address:999 Linxian Road, Jinshan Industrial Park, Shanghai, China
Zhengzhou Institute of Chiral Pharmer Research Co., Ltd.
Contact:86-371-55219111
Address:15 Floor, 2 Building, Central China Technovalley, Zhongyuan West Road
Jewim Pharmaceutical (Shandong) Co., Ltd
Contact:+8615621883869
Address:山东省泰安市高新技术产业开发区配天门大街西首
Shenyang Mole pharmaceutical Technology Development Co.,Ltd
Contact:+86-24-31204918/13889278616
Address:No.44, wanliutang road, shenhe District of Shenyang
BAODING SINO-CHEM INDUSTRY CO.,LTD
Contact:0312-5956088
Address:NO.8 FUXING ROAD,CHINA
Doi:10.1039/b413724h
(2005)Doi:10.1016/j.bmcl.2018.03.051
(2018)Doi:10.1002/ejoc.200400630
(2005)Doi:10.1248/cpb.56.176
(2008)Doi:10.1016/j.jorganchem.2004.08.047
(2005)Doi:10.1021/jo00158a025
(1983)